CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 1.59: grey zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
452.92MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.88xvs all stocks
52-Week Change
92.51%vs all stocks
Market Capitalization
452.92MUSDvs all stocks (USD)
Enterprise Value
250.23MUSDvs all stocks (USD)
Forward P/E
-2.52xvs Biotechnology peers
Price to Book (MRQ)
2.31xvs Biotechnology peers
Enterprise to EBITDA
-1.54xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-39.55%vs Biotechnology peers
Return on Equity (TTM)
-74.55%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
-126.36MUSDvs all stocks (USD)
EBITDA (TTM)
-162.14MUSDvs all stocks (USD)
Net Income (TTM)
-156.40MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-150.39MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-93.76MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-169.83MUSDvs all stocks (USD)
Pre-tax Income
-161.31MUSDFY2025 · Dec 31, 2025Net Income
-161.31MUSDFY2025 · Dec 31, 2025EBIT
-160.82MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-159.02MUSDFY2025 · Dec 31, 2025Research & Development
133.72MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
36.11MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
9.09MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
489.00KUSDFY2025 · Dec 31, 2025EPS (Basic)
-3.64USDFY2025 · Dec 31, 2025EPS (Diluted)
-3.64USDFY2025 · Dec 31, 2025Basic Shares Outstanding
44.26MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
44.26MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-161.31MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-150.23MUSDFY2025 · Dec 31, 2025Free Cash Flow
-150.30MUSDDerived from operating cash flow minus capital expenditure. This filing charges 1.8M of depreciation against 65K of capital expenditure, and its own free-cash-flow line reads -154.85M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
124.64MUSDFY2025 · Dec 31, 2025Interest Paid
415.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-161.31MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.80MUSDFY2025 · Dec 31, 2025Stock-based Compensation
10.08MUSDFY2025 · Dec 31, 2025Other Non-cash Items
2.97MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
543.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-4.32MUSDFY2025 · Dec 31, 2025Capital Expenditures
65.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-364.62MUSDFY2025 · Dec 31, 2025Sale of Investments
405.70MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
41.14MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-808.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
-619.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
139.18MUSDFY2025 · Dec 31, 2025Shares Outstanding
60.53MSharesUpdated Jul 19, 2026Float Shares
35.55MSharesUpdated Jul 19, 2026Shares Short
7.22MSharesUpdated Jul 19, 2026Short Ratio
6.26daysvs all stocks
Short % of Shares Outstanding
13.99%vs all stocks
% Held by Insiders
7.10%vs all stocks
% Held by Institutions
74.72%vs all stocks
Total Cash (MRQ)
236.45MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
3.89USDUpdated Jul 19, 2026Total Debt (MRQ)
33.76MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1726xvs Biotechnology peers
Current Ratio (MRQ)
8.15xvs Biotechnology peers
Book Value per Share (MRQ)
3.23USDUpdated Jul 19, 2026Total Assets
293.83MUSDvs all stocks (USD)
Total Current Assets
282.95MUSDFY2025 · Dec 31, 2025Total Liabilities
61.55MUSDFY2025 · Dec 31, 2025Total Non-current Assets
10.87MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
25.06MUSDFY2025 · Dec 31, 2025Total Current Liabilities
36.49MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
124.09MUSDFY2025 · Dec 31, 2025Other Short-term Investments
155.16MUSDFY2025 · Dec 31, 2025Accounts Payable
5.31MUSDFY2025 · Dec 31, 2025Short-term Debt
3.97MUSDFY2025 · Dec 31, 2025Long-term Debt
25.06MUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-424.83MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
232.28MUSDvs all stocks (USD)
52-Week Low
2.80USDUpdated Jul 19, 202652-Week High
13.67USDUpdated Jul 19, 202652-Week Change
92.51%vs all stocks
Beta
1.88xvs all stocks
50-Day MA
8.65USDUpdated Jul 19, 2026200-Day MA
8.21USDUpdated Jul 19, 2026Avg 10-Day Volume
1.35MSharesUpdated Jul 19, 2026Avg 30-Day Volume
1.23MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-3.27USDUpdated Jul 19, 2026Other Income / Expense
-85.00KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 1.59: grey zoneSignificant
Altman Z-Score: 1.59
Low earnings qualitySignificant
Earnings Quality Score: -0.51
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Allergy Therapeutics plc
Tier 1ProductionApproval-Gated PipelineRule
Prothena Corporation plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Ever Supreme Bio Technology Co., Ltd
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Shouxiangu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
ClearPoint Neuro Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Nanjing Medlander Medical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cybin Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Guizhou Yibai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Honz Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Editas Medicine Inc.
Tier 1ProductionApproval-Gated PipelineRule